Recombinant antigens from mumps virus and their use in vaccines

Details Recombinant antigens from mumps virus and their use in vaccines Recombinant antigens from mumps virus and their use in vaccines

C - Chemistry, Metallurgy

12

N

C12N 15/45 (2006.01) A61K 39/165 (2006.01) C07K 14/12 (2006.01) C07K 19/00 (2006.01) C12N 5/10 (2006.01) C12N 15/62 (2006.01) C12N 15/86 (2006.01) A61K 39/00 (2006.01)

Patent

CA 2161645

The invention provides recombinant DNA encoding an antigen of mumps virus selected from the group comprising: (a) the full length fusion protein (F), complete with signal peptide(s) and membrane anchor domain (a) (designated herein as Fs+a+); the full length attachment protein or hemagglutinin-neuraminidase (HN); the full length nucleocapsid protein (NP); (b) the truncated fusion protein lacking the membrane anchor domain (herein designated Fs+a-); (c) a hybrid protein derived by fusion of the F, HN and/or NP proteins or portions thereof. Also within the scope of the invention are vectors comprising the DNA of the invention and a host such as a vaccinia virus, mammalian cell or bacterial cell transformed or transfected with the vector, and proteins expressed by the hosts.

Affiliated with

Also associated with

Rating

Recombinant antigens from mumps virus and their use in vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant antigens from mumps virus and their use in vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant antigens from mumps virus and their use in vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1344242